MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
NCT07880379
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a single-center, open-label clinical study designed to evaluate alpha-synuclein (ASYN) deposition in the brain of participants with Parkinson's disease (PD), as compared with healthy elderly (HE) participants. Up to 18 participants (12 PD, 6 HE) are planned to be enrolled. Each participant will receive a single IV injection of [¹⁸F]MK-0947 as part of Part 1A followed by PET imaging using the Investigational United Imaging NeuroEXPLORER(NX) camera or the Siemens Biograph mCT camera.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinsons Disease (PD)
- Healthy Elderly Volunteers
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- XingImaging, LLC
- Last updated on ClinicalTrials.gov
- October 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- XingImaging, LLC · New Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.